SESSION I
Myelodysplastic syndromes
M. Cazzola
Organ damage and iron overload
E. Angelucci, C. Cogoni, M. Pettinau, F. Pilo, C. Targhetta, F. Zacchedu
Progress in the management of iron overload in erytrocyte disorders
M.D. Cappellini, E. Cassinerio, L. Zanaboni, G. Fabio, P. Pattoneri
SESSION II
Ph Positive-Leukemias
F. Guilhot, L. Roy, J. Guilhot, P-J. Saulnier, J-M. Gombert, A. Turhan
Thyrosin kinase inhibitors: nilotinib
F. Castagnetti, F. Palandri, G. Gugliotta, A. Poerio, M. Amabile, S. Soverini, G. Martinelli,
M. Baccarani, G. Rosti
New drugs to overcome meccanisms of resistance in Ph+ leukemia: bosutinib
G. Martinelli, I. Iacobucci, D. Cilloni, P. Giannoulia, S. Soverini, P.P. Piccaluga,
C. Papayannidis, S. Paolini, C. Terragna, M. Amabile, S. Colarossi, A. Gnani, F. Pane,
G. Saglio, M. Baccarani
SESSION III
Peripheral T-cell lymphomas
S.A. Pileri, C. Agostinelli, C. Campidelli, F. Bacci, E. Sabattini, A. Pileri jr, P.P. Piccaluga
A Phase II international, multicenter study of oral panobinostat (LBH589)
in patients with refractory cutaneous T-cell Lymphoma
M.G. Bernengo, F. Vanaclocha, M. Duvic, T. Kuzel, F. Kerdel, L. Pinter-Brown, A. Bosly,
C. Okada, D. Breneman, P.L. Zinzani, J. Becker, L. Hughey, M. Ardaiz, J. Zain, L. Zhang,
S. Hirawat, G. Laird, D. Johnson, H.M. Prince
SESSION IV
Chronic lymphocytic leukemia
F. Caligaris-Cappio
Monoclonal antibodies (update): cd20, rituximab
A. Hagenbeek
90Y-ibritumumab tiuxetan (Zevalin)
P.L. Zinzani
Update of alemtuzumab in the treatment of chronic lymphocytic leukaemia
C. Dearden
Immunotherapy with epratuzumab in B-cell non-Hodgkin’s lymphoma
P. Martin, D. Goldenberg, J.P. Leonard
New agents for the treatment of acute myeloid leukemia: gemtuzumab ozogamicin
S. Amadori
SESSION V
Update on galiximab: anti-cd80 monoclonal antibody
M.S. Czuczman
CMC-544 (inotuzumab ozogamicin): a CD-22-targeted immunoconjugate
of calicheamicin
J.F. DiJoseph, K. Khandke, M.M. Dougher, D.Y. Evans, D.C. Armellino,
P.R. Hamann, N.K. Damle
Monoclonal antibodies (novel): humax-cd20, ofatumumab
A. Hagenbeek
Lumiliximab in chronic lymphocytic leukemia
T.S. Lin
Bevacizumab as an anti-vegf strategy in lymphoma
S.J. Horning
HuMax-CD38, a new human CD38 monoclonal antibody, effectively mediates killing
of multiple myeloma and plasma cell leukemia cells
P.W.H.I. Parren
SESSION VI
Individualizing therapy for the hematologic malignancies: the stuff of genes and dreams
B.D. Cheson
Aurora kinase inhibitor: AS703569
A. Gianella-Borradori
Pha-739358: a pan-aurora kinase inhibitor
R. Paquette, N. Shah, C. Sawyers, G. Martinelli, J. Nicoll, M. Chalukya, G. Locatelli, L. Capolongo, J. Moll, S. Comis, B. Laffranchi
SESSION VII
From cell biology to therapy: lenalidomide in untreated multiple myeloma
A. Palumbo, P. Falco, F. Gay, V. Magarotto, F. Patriarca, C. Nozzoli, M. Boccadoro
From cell biology to therapy: lenalidomide in relapsed/refractory multiple myeloma
P. Richardson, T. Hideshima, C. Mitsiades, R. Schlossman, J. Laubach, I. Ghobrial, N. Raje,
N. Munshi, K. Anderson
From cell biology to therapy: forodesine
M. Duvic
Flavopiridol (alvocidib) in chronic lymphocytic leukemia
T.S. Lin, B. Fischer, K.A. Blum, M. Brooker-McEldowney, M.E. Moran, L.A. Andritsos, J.M. Flynn, M.A. Phelps, J.T. Dalton, A.J. Johnson, S.M. Mitchell, L.L. Smith, A.J. Wagner, C.A. Raymond, A.D. Colevas, M.R. Grever, J.C. Byrd 112
mTOR inhibitors for the treatment of lymphoma
T.E. Witzig
SESSION VIII
Multiple myeloma
J. San Miguel
Proteasome inhibitors: bortezomib in multiple myeloma
M. Cavo, M.C. Pallotti, L. Pantani, A. Petrucci, A. Brioli, C. Terragna, N. Testoni, G. Marzocchi, S. Durante, G. Perrone, P. Tacchetti, E. Zamagni, P. Tosi, M. Baccarani
Bortezomib in lymphomas
A. Goy
Proteasome inhibitors: beyond nfkb inhibition alone and the emerging role
of combination therapy in the treatment of multiple myeloma
P. Richardson, C. Mitsiades, J. Laubach, C. Conant, T. Hideshima, D. Chauhan, R. Schlossman, I. Ghobrial, N. Munshi, K.C. Anderson
Novel proteasome inhibitors
P. Tosi, M.C. Pallotti, L. Pantani, A. Petrucci
SESSION IX
Decitabine in myeloid malignancies
H.I. Saba
Tipifarnib in hematologic malignancies
J-L. Harousseau
SESSION X
Is there a role for immunotherapy in Hodgkin’s disease?
B. Böll, A. Engert
New agents for the treatment of acute myeloid leukemia: midostaurin
S. Amadori
Lestaurtinib as a FLT3 Inhibitor
A.K. Burnett